Arginase-1 (SP156) Rabbit Monoclonal Antibody

Arginase-1
Arginase-1 (SP156) on liver, cirrhosis.

Arginase-1 (SP156) Rabbit Monoclonal Antibody

Specialties: Anatomic Pathology Gastrointestinal (GI) Pathology

Updated: 2018-01-11 08:31:20

Arginase-1 is a key urea cycle metalloenzyme that has demonstrated expression in normal human liver with a high degree of specificity.1-2  Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver accounting for an estimated 70%-85% of total liver cancers worldwide.3-4  Diagnostic pitfalls exist in the morphologic distinction of HCC from other hepatocellular and non-hepatocellular lesions. In difficult or equivocal cases, the application of immunohistochemical (IHC) panels has been shown to aid in the distinction of benign and malignant liver lesions.5-10  In sections of normal liver, anti-arginase-1 produced strong, diffuse cytoplasmic reactivity in all hepatocytes throughout the lobule. In some cases, patchy nuclear reactivity is also evident in hepatocytes along with the cytoplasmic reactivity.1,2  Reactivity is not observed in bile duct epithelial cells, sinusoidal endothelial cells, Kupffer cells, or vascular endothelial cells. In sections of HCC, anti-arginase-1 produces cytoplasmic or cytoplasmic plus nuclear reactivity.11,12

  1. Multhaupt H, et al. Immunohistochemical localisation of arginase in human liver using monoclonal antibodies against human liver arginase. Histochemistry. 1987; 87:465-70.
  2. Sekine S, et al. Dicer is required for proper liver zonation. J Pathol. 2009; 219:365-72.
  3. Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
  4. Ferrel L. "Benign and malignant tumors of the liver." Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Philadelphia, PA: Saunders Elsevier Inc., 2009. 1291-325. Print.
  5. Wee A. Fine needle aspiration biopsy of the liver: Algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma. Cytojournal. 2005; 2:7.
  6. Wee A. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology. 2011; 22:287-305.
  7. Niemann TH, et al. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma. Cancer. 1999; 87:295-8.
  8. Onofre AS, et al. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Cancer. 2007; 111:259-68.
  9. Nassar A, et al. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009; 37:629-35.
  10. Zimmerman RL, et al. Diagnostic value of hepatocyte paraffin 1 antibody to discriminate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsies of the liver. Cancer. 2001; 93:288-91.
  11. Radwan NA, et al. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol. 2012; 7:149.
  12. Nguyen T, et al. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma. Arch Pathol Lab Med. 2015; 139:1028-34.

Specifications


  • Reactivity: paraffin
  • Control: Normal Liver (Cytoplasmic, Nuclear); Hepatocellular Carcinoma (Cytoplasmic, Nuclear)
  • Dilution Range: 1:25-1:100 *

Package Inserts


IFU SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

25.0 mL predilute ready-to-use380R-10
0.1 mL concentrate380R-14
0.5 mL concentrate380R-15
1.0 mL concentrate380R-16
1.0 mL predilute ready-to-use380R-17
7.0 mL predilute ready-to-use380R-18

For in vitro diagnostic (IVD) use in Canada

25.0 mL predilute ready-to-use380R-10
0.1 mL concentrate380R-14
0.5 mL concentrate380R-15
1.0 mL concentrate380R-16
1.0 mL predilute ready-to-use380R-17
7.0 mL predilute ready-to-use380R-18

For in vitro diagnostic (IVD) use in Europe

25.0 mL predilute ready-to-use380R-10
0.1 mL concentrate380R-14
0.5 mL concentrate380R-15
1.0 mL concentrate380R-16
1.0 mL predilute ready-to-use380R-17
7.0 mL predilute ready-to-use380R-18

For research use only (RUO) in Japan

25.0 mL predilute ready-to-use (RUO)380R-10-RUO
0.1 mL concentrate (RUO)380R-14-RUO
0.5 mL concentrate (RUO)380R-15-RUO
1.0 mL concentrate (RUO)380R-16-RUO
1.0 mL predilute ready-to-use (RUO)380R-17-RUO
7.0 mL predilute ready-to-use (RUO)380R-18-RUO

 

To request information on this product in additional countries, please click the button below.

Request More Information